Tumor specific antibody conjugates and uses therefor
AssigneesThe University of North Carolina at Charlotte, OncoTAb, Inc.
InventorsPinku Mukherjee, Jordon Wang, Kexin Huang, Yan HE
Life of this patent
Estimating the term…
Loading patent…
AssigneesThe University of North Carolina at Charlotte, OncoTAb, Inc.
InventorsPinku Mukherjee, Jordon Wang, Kexin Huang, Yan HE
Estimating the term…
Provided are antibodies, and fragments, derivatives, and nanoparticle conjugates thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.
A humanized antibody, or an antigen-binding fragment thereof, that binds to a tumor-exclusive epitope of mucin-1 (MUC1) polypeptide, comprising:
A chimeric antigen receptor (CAR) molecule comprising an antigen-binding domain (BD) that binds to a tumor-exclusive epitope of a human MUC1 polypeptide (tMUC), a transmembrane domain (TD), and an intracellular signaling domain (ISD), wherein the BD comprises a heavy chain amino acid sequence at least 95% identical to amino acids 25-142 of SEQ ID NO:
Dependencies are inferred from the claim text.